Abstract Library

#4455 Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC

Introduction: HG-GEP-NEN are classified into neuroendocrine tumours grade 3 (NET G3) and neuroendocrine carcinomas (NEC). This distinction is crucial as it affects patient prognosis and treatments but can be challenging.

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Solstad O, Oudijk L, Bräutigam K, Bani M,

Keywords: HG-GEP-NEN, neuroendocrine neoplasm, NEC, NET G3, Classification, Review, criteria, diagnosis, pathology,

#3887 Characteristics and management of high grade gastroenteropancreatic neuroendocrine neoplasms – A Belgian retrospective analysis from the DNET & NETwerk registry

Introduction: High grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEPNEN) comprise neuroendocrine carcinoma (NEC) and well-differentiated neuroendocrine tumors (NETG3). These entities exhibit many differences in behaviour, prognosis and sensitivity to chemotherapy. Data about their optimal management are still scarce.

Conference:

Presenting Author:

Authors: Islam O, Sarti K, Verslype C, van Laethem J, Kalantari Hassan R,

Keywords: Neuroendocrine tumor, high-grade gastroenteropancreatic NEN (HG GEPNEN), neuroendocrine carcinoma, neuroendocrine tumor g3, retrospective data, clinical data, pathology,

#3717 Results of NETest liquid biopsy in high-grade gastroenteropancreatic neuroendocrine neoplasms

Introduction: Molecular blood biomarkers are lacking for high-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN), and morphologically separating between neuroendocrine carcinoma (NEC), neuroendocrine tumors (NET G3), adenocarcinoma and MINEN frequently difficult. The mRNA-based NETest has diagnostic, prognostic and predictive value in neuroendocrine tumors G1-2 but has not been studied in HG GEP-NEN.

Conference:

Presenting Author: Sorbye H

Authors: Sorbye H, Langer S, Hjortland G, Vestermark L, Sundlov A,

Keywords: NETest, high-grade, gastroenteropancreatic, neuroendocrine carcinoma, NET G3, neuroendocrine neoplasm, biomarker,

#3712 Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms

Introduction: High-grade gastroenteropancreatic (HG-GEP) neuroendocrine neoplasms (NEN) are aggressive cancers with a dismal prognosis. The molecular etiology remains poorly characterized and prevalence of pathogenic germline variants unknown.

Conference:

Presenting Author: Sorbye H

Authors: Sorbye H, Venizelos A, Perren A, Couvelard A, Hjortland G,

Keywords: germline, mutations, gastropancreatic, neuroendocrine carcinoma, NET G3, high-grade,

#3507 Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)

Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN) consist of poorly differentiated neuroendocrine carcinoma (NEC) and well-differentiated neuroendocrine tumors (NET G3). Platinum/etoposide has been the cornerstone of treatment in advanced cases, but show limited benefit for patients when tumors have Ki-67 ≤55%.

Conference:

Presenting Author:

Authors: Morken S, Langer S, Sundlöv A, Detlefsen S, Krogh M,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade gastroenteropancreatic, everolimus, temozolomide,